Edavit Injection (Edaravone).

• Composition :
  Each Edavit injection contains Edaravone 1.5 mg/ml Injection.
• Indications :
  For the improvement of neurological symptoms, disorder of activities of daily living, and functional disorder associated with acute ischaemic stroke.
• Pharmacodynamics :
  Edaravone scavenges free hydroxyl radicals and peroxynitrite radicals which are highly associated with neuronal damage/death from many cerebral vascular disorders such as ischemic strokes. It exerts a neuroprotective and antioxidant effect and delays disease progression by limiting the extent of lipid peroxidation via free radical generation and cell membrane damage from oxidative stress. It reversed the reduction in regional blood flow and cerebral edema in a case of ischemic stroke.
• Dosage and administration :
  The recommended dosage is 60 mg administered as an intravenous infusion over 60 minutes as follows: Initial treatment cycle: daily dosing for 14 days followed by a 14- day drug-free period. Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods.
• Contraindications :
  Patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Edavit.
• Precautions and warnings :
  Caution is recommended in patients with hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported patients should be monitored carefully for hypersensitivity reactions, Sulfite allergic Reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy: No adequate data on the developmental risk associated with the use of Edavit in pregnant women. Lactation: No data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Safety and effectiveness of Edavit in pediatric patients have not been established.
• Drug interactions :
  At clinical dose, edaravone and its metabolites are not expected to significantly inhibit cytochrome P450 enzymes. Edaravone and its metabolites are not expected to induce CYP1A2, CYP2B6, or CYP3A4 at the clinical dose.
• Adverse reactions :
  Most common adverse effects are confusion, gait disturbance, and headache.
• Therapy Area :
  Cerebral Activators_Nootropics